The seminal observation that blocking the prototypical immune checkpoint receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) could mediate tumor regression in murine models (10) led to the clinical development and approval of anti-CTLA-4 as a treatment for patients with advanced melanoma (11). Here, CTLA4 is linked to melanoma.